Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Feb 05, 2021 11:50am
98 Views
Post# 32484237

RE:RE:RE:RE:RE:Nomination

RE:RE:RE:RE:RE:NominationThanks for the nomination Palin but since I am still not to the last stage of grief, I would likely only cause a unhealthy disturbance if I were granted the opportunity to ask questions, which will never happen for any of us anyway.

It is quite unfortunate that the analyst coverage on THTX is so weak and, even worse, is getting weaker. Given the phase III NASH and now Fasat Tracked phase I cancer, you would think it should not be too hard to find a number of analysts to cover the stock. Not being able to do so has cost us dearly and then the deal seemed to be constructed in a way to make sure the leverage of a deal to attract analyst coverage was totally squandered. Given the choices that are being made, is it any wonder the quarterly calls, let alone the company altering call on the company's decision to pursue the general NASH market, get no real interest from the institutional investment community. How long can this go on without being addressed???? Substandard/inadequate/disinterested analyst coverage of TH has been a standard feature for a very long time. 

The deal showed us that we believe more in TH's prospects than TH leadership does. Until that attitude changes, it is hard to see the quarterly conference calls becoming very vibrant or attracting a higher level of analytical talent. 

palinc2000 wrote:

Quaterly CCs s should last more than a few minutes ...Having 2  uninterested sell side analysts mostly asking one or two questions benefit no one..
 

 

scarlet1967 wrote: What CYDY is doing is working anyway I am going to schedule a call with Leah discussing their marketing and communication strategies. I won't discuss the deal as they did give their rationale justifying it earlier and I don't think she will be adding anything meaningful re the deal.
I just want to see how open they are to approach a more retail friendly approach.

 

palinc2000 wrote:

Questions from investors are frequently allowed during Investors Day and it seems to me that having a representative of a Fund holding more than 6 million shares and an investor with your background  would  help not only other investors but also the Company....They could make whatever rules they want

 

Wino115 wrote: They've never let anyone other than sell-side analysts ask questions. I don't think that will change anytime soon and seems to be standard now given some of the crazy histrionics past calls on other controversial stocks had. I guess the lawyers have just decided it's better to shut it off for the general public. Only guys like Cytodyn let anyone ask a question, but that's because no sell side would associate with them.
 

 

palinc2000 wrote: I hereby nominate Spceo1 and Wino as representatives pf posters on this MB to ask questions during the Theratech 's CC s 
All those in favor please vote

PS Of course I presume that both nominees are willing to act on our behalf

 

 

 




<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse